In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

In a bid to claw back $2.15 billion, the struggling pharmaceutical giant Bayer CEO is doing away with middle managers and 99% of the company’s 1,362-page corporate handbook, allowing nearly ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...

Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

The US government banned the chemicals in 1979 ... Monsanto - which is owned by German pharmaceutical company Bayer - was ordered to pay $73 million in compensatory damages, and $112 million ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

The global antiplatelet market value stood at US$3.53 billion in 2023 ... and an increasing focus on preventive healthcare strategies. The growing number of individuals with a history of CVD ...